转换为C.E.R.A.治疗后的血红蛋白稳定性和患者满意度：一项多中心观察性研究。 - Suppr

Suppr

超能文献

Hemoglobin stability and patient satisfaction after switch to C.E.R.A. therapy: a multicenter, observational study.

作者信息

Bozkurt Fuat, Fink Heribert-Ewald

机构信息

Nephrologisches Zentrum, Daun, Germany,

出版信息

Clin Drug Investig. 2013 Dec;33(12):939-40. doi: 10.1007/s40261-013-0142-5.

DOI:10.1007/s40261-013-0142-5

PMID:24129666

Abstract

摘要

相似文献

Hemoglobin stability and patient satisfaction after switch to C.E.R.A. therapy: a multicenter, observational study.

Clin Drug Investig. 2013 Dec;33(12):939-40. doi: 10.1007/s40261-013-0142-5.

Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.

Clin Drug Investig. 2012 Feb 1;32(2):99-110. doi: 10.2165/11594040-000000000-00000.

Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

Curr Med Res Opin. 2007 May;23(5):969-79. doi: 10.1185/030079907x182103.

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2.

Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.

Adv Ther. 2016 Apr;33(4):610-25. doi: 10.1007/s12325-016-0309-6. Epub 2016 Mar 10.

Erythropoiesis-stimulating agents in renal medicine.

Oncologist. 2011;16 Suppl 3:19-24. doi: 10.1634/theoncologist.2011-S3-19.

Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.

Med Arch. 2020 Apr;74(2):109-114. doi: 10.5455/medarh.2020.74.109-114.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. doi: 10.2215/CJN.03631006. Epub 2007 May 23.

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

Clin Ther. 2007 Apr;29(4):626-39. doi: 10.1016/j.clinthera.2007.04.014.

C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.

Int Urol Nephrol. 2013 Oct;45(5):1355-64. doi: 10.1007/s11255-012-0272-3. Epub 2012 Sep 19.

本文引用的文献

Clin Drug Investig. 2012 Feb 1;32(2):99-110. doi: 10.2165/11594040-000000000-00000.

Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients.

Hemodial Int. 2012 Jan;16(1):11-9. doi: 10.1111/j.1542-4758.2011.00608.x.

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

Nephrol Dial Transplant. 2011 Dec;26(12):3980-6. doi: 10.1093/ndt/gfr160. Epub 2011 Apr 19.

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.

Nephrol Dial Transplant. 2010 Dec;25(12):4009-17. doi: 10.1093/ndt/gfq305. Epub 2010 Jun 3.

Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study.

Curr Med Res Opin. 2010 May;26(5):1083-9. doi: 10.1185/03007991003666652.

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

Lancet. 2007 Oct 20;370(9596):1415-21. doi: 10.1016/S0140-6736(07)61599-2.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. doi: 10.2215/CJN.03631006. Epub 2007 May 23.

Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

Curr Med Res Opin. 2007 May;23(5):969-79. doi: 10.1185/030079907x182103.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验